logo

For the Inventor, By the Inventor

Stockholm, Sweden

Biogaia Ab


USPTO Granted Patents = 51

% Expired Patents = 13.7



Trademarks = 9

Forward Citations = 280

Loading Chart...
Loading Chart...

39 inventors (with patents filed for the assignee):

goldMedal Bo Mollstam (19 out of 26 patents)

silverMedal Eamonn Connolly (18 out of 22 patents)

bronzeMedal Stefan Roos (9 out of 11 patents)

4.  Wolfgang Kunze (6 out of 6 patents)

5.  John Bienenstock (6 out of 9 patents)

6.  Bo Möllstam (5 out of 5 patents)

7.  James Versalovic (4 out of 4 patents)

8.  Elisabeth Sjoberg (4 out of 6 patents)

9.  Ivan A Casas (4 out of 10 patents)

10.  Robert Allen Britton (3 out of 3 patents)

11.  Laura Rae McCabe (3 out of 4 patents)

12.  Bernard Berger (2 out of 7 patents)

13.  Clara Lucia Garcia-Rodenas (2 out of 31 patents)

14.  Melissa Lepage (2 out of 3 patents)

15.  Catherine Ngom-Bru (2 out of 5 patents)


Core Competencies:
Melatonin Supporting Bacteria
Infantile Colic
Diabetes Treatment
Probiotic Cultures
Lactic Acid Bacteria
Gastrointestinal Pain
Microbiota Dysbiosis
Allergy Treatment
Histamine Production
Dental Caries
T-Reg Deficiency
Enteropathogenic Infections

51 patents:

1. 12642830 - Selection and Use of Melatonin Supporting Bacteria to Reduce Infantile Colic (2026-06-02),
2. 12318412 - andfor use in the treatment or prevention of diabetes and bowel diseases (2025-06-03),
3. 12295975 - Serotonin producing bacteria (2025-05-13),
4. 12201656 - Selection of bacterial strains useful in allergy treatment (2025-01-21),
5. 11976268 - Method for adaptation (2024-05-07),
6. 11911424 - Selection and use of melatonin supporting bacteria to reduce infantile colic (2024-02-27),
7. 11857582 - Therapeutic microvesicles of probiotic bacteria (2024-01-02),
8. 11730780 - Lactic acid bacteria, methods and uses thereof (2023-08-22),
9. 11701397 - Use offor recovery of microbiota dysbiosis in early life (2023-07-18),
10. 11602551 - Use of inosine for the treatment of t-reg deficiency (2023-03-14),
11. 11371985 - Selection of agents modulating gastrointestinal pain (2022-06-28),
12. 11369646 - Use offor recovery of microbiota dysbiosis in early life (2022-06-28),
13. 11285181 - Lactic acid bacteria, methods and uses thereof (2022-03-29),
14. 11135255 - Selection of bacterial strains useful in allergy treatment (2021-10-05),
15. 10898529 - Production and use of bacterial histamine (2021-01-26),
Biogaia AB, headquartered in Stockholm, specializes in the development and manufacturing of probiotic bacteria aimed at enhancing health and well-being. The company focuses on innovative solutions for various health issues, including gastrointestinal pain, infantile colic, and allergies. Its core technologies encompass melatonin-supporting bacteria and lactic acid bacteria, addressing conditions such as microbiota dysbiosis and diabetes treatment. Biogaia's commitment to research and development positions it as a leader in the probiotic sector.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Biogaia Ab
51 Patents

#20 in Stockholm

#136 in Sweden

#13,766 in the World

Stockholm, SE
Stockholm, Sweden

Biogaia Ab

Forward Citations = 280

39 inventors:

goldMedal Bo Mollstam (19 out of 26 patents)

silverMedal Eamonn Connolly (18 out of 22 patents)

bronzeMedal Stefan Roos (9 out of 11 patents)

4.  Wolfgang Kunze (6 out of 6 patents)

5.  John Bienenstock (6 out of 9 patents)

Please report any incorrect information to [email protected]
Loading…